It’s been a little over three months since The Lancet published the global consensus renaming PCOS to PMOS — polyendocrine metabolic ovarian syndrome. Enough time has passed that the initial coverage cycle is over, which makes it a reasonable moment to ask an unglamorous question: what, concretely, has changed?
I’m not going to pretend the answer is “everything,” and I’d be skeptical of anyone claiming it is. A name change published in May doesn’t rewrite an electronic health record system, retrain a primary care physician, or update an insurance billing code by August. That’s not a criticism of the process — it’s just how health system change actually moves, and it’s worth saying plainly instead of implying more has happened than has.
What’s real
The reclassification itself is substantive, not cosmetic. This wasn’t a rebrand — it was a multistep global consensus process spanning collaboration across 56 academic, clinical, and patient organizations, built on survey responses from more than 14,300 patients and health professionals worldwide. The name itself does real conceptual work: “polyendocrine” corrects the false impression that this is a single-hormone, ovary-only condition; “metabolic” puts insulin resistance and cardiovascular risk into the name instead of leaving them as an asterisk; and dropping “polycystic” removes a term that never accurately described the ultrasound finding in the first place — those aren’t pathological cysts, they’re arrested follicles, and the mislabeling has been a documented source of diagnostic confusion for decades. [certain]
What’s still mostly on paper
The authors were explicit that this doesn’t happen overnight. They laid out an 8-stage implementation plan, and as of today, we’re still in the early stages of it: publication and academic dissemination, and the beginning of resource co-design. The stages that actually touch daily clinical practice — EHR integration, clinician education programs, insurance and coding alignment, and formal adoption into disease classification systems like the ICD — are scheduled for later stages, with a managed 3-year transition window and full integration into the International Guideline not expected until 2028.
So if you ask your own OB/GYN or endocrinologist this week whether they’re charting “PMOS,” the honest answer for most of them right now is probably still “PCOS,” and that’s not a failure — it’s stage 1 of an 8-stage plan working roughly on schedule. [likely]
Why this piece exists
Most of the coverage in May treated the name change as the finish line. It wasn’t — it was the starting gun. The interesting question isn’t “did the name change,” which already happened and is done. It’s “does behavior change,” which is the thing the reclassification’s own authors said should be the actual measure of success, not terminology uptake on its own.
That’s what the rest of this series is going to track: not whether people are saying PMOS instead of PCOS, but whether the infrastructure underneath patient care — diagnosis speed, billing, guidelines, medical education — actually moves.
Next: the real roadmap, stage by stage, and what to actually watch for between now and 2028.
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.